Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975933 | 0.80 | TMEM97 (0.49) | TMEM97SIGMAR1PRCPSMN1; SMN2ELANE | |
| SCHEMBL4336812 | 0.78 | HTR2C (0.47) | TMEM97SIGMAR1HTR2CTSHRL3MBTL1 | |
| SCHEMBL4315505 | 0.77 | KMT2A (0.52) | HTR2CPRCPTSHRKDM4ELMNA | |
| SCHEMBL4326533 | 0.76 | HTR2C (0.43) | TMEM97SIGMAR1HTR2CPRCPTSHR | |
| SCHEMBL30292457 | 0.75 | HTR2C (0.49) | TMEM97SIGMAR1HTR2CPRCPSMN1; SMN2 | |
| SCHEMBL1190724 | 0.74 | HTR2C (0.53) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1189368 | 0.74 | HTR2C (0.53) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1190728 | 0.74 | HTR2C (0.53) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL28433612 | 0.74 | KMT2A (0.51) | HTR2CPRCPTSHRKDM4ELMNA | |
| SCHEMBL4389072 | 0.72 | KMT2A (0.53) | HTR2CTSHRKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553975-B2 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2009-06-30 | — | — | US | disclosed |
| US-7323484-B2 | Farnesyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2008-01-29 | — | — | US | disclosed |
| US-20060252760-A1 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-11-09 | — | — | US | disclosed |
| US-20060079530-A1 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-04-13 | — | — | US | disclosed |
| US-7022704-B2 | 5,6,7, 8-tetrahydro-imidazo-(1,2a)-pyrazine derivative; useful for treating restenosis and tumor | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2006-04-04 | — | — | US | disclosed |
| EP-0904274-B1 | FARNESYL TRANSFERASE INHIBITORS | CONSEILS DE RECH SET D APPLIC (FR) | 2005-05-25 | — | — | EP | disclosed |
| US-6673927-B2 | FOR THERAPY OF TUMOR OR RESTENOSIS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2004-01-06 | — | — | US | disclosed |
| US-20030119864-A1 | Farnesyl transferase inhibitors | BIOMEASURE INCORPORATED, A MASSACHUSETTS CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20020013319-A1 | FARNESYL TRANSFERASE INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2002-01-31 | — | — | US | disclosed |
| EP-0904274-A4 | FARNESYL TRANSFERASE INHIBITORS | BIOMEASURE INC (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0904274-A1 | FARNESYL TRANSFERASE INHIBITORS | Biomeasure Incorporated (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997030053-A9 | FARNESYL TRANSFERASE INHIBITORS | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997030053-A1 | FARNESYL TRANSFERASE INHIBITORS | BIOMEASURE INCORPORATED (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079530-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | TMEM97 2769/4885SIGMAR1 4516/4885HTR2C 4862/4885 |
| US-20060252760-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | TMEM97 2769/4885SIGMAR1 4516/4885HTR2C 4862/4885 |
| US-20030119864-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | TMEM97 2769/4885SIGMAR1 4516/4885HTR2C 4862/4885 |
| US-20020013319-A1 | FARNESYL TRANSFERASE INHIBITORS | FNTB, FNTA, LCAT | TMEM97 2769/4885SIGMAR1 4516/4885HTR2C 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.